Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease
Part of paid clinical trials in Stanford, California.
- Sponsor
- Stanford University
- Study ID
- NCT06269055
- Status
- Recruiting
Conditions
- Ca-DTPA
- Gadolinium Deposition Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Interview — OTHERTelephone interview and questionnaires about the results and side effects experienced
Study Details
This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA).
Key Dates
- Start date
- Dec 2, 2024
- Status verified
- May 2025
- Primary completion
- May 31, 2026
- Completion
- May 31, 2026
Study Design
- Enrollment
- 50 participants (estimated)
Primary Outcome Measure
Rating of Gadolinium Deposition Disease Symptoms at start of GDD and currently [ Time Frame: Two or more weeks after the last of 5 of more DTPA chelation treatments ]
Central Contacts
- Lorrin M Koran, MD650 321-6804
- Jarrod Ehrie, MD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University Medical Center | Stanford | California | 94305 |
Find similar trials in Stanford, CA
By research site